Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---

+ Andere Auflagen/Ausgaben
heiBIB
 Online-Ressource
Verfasst von:Grauer, Oliver Martin [VerfasserIn]   i
 Pascher, Christina [VerfasserIn]   i
 Hartmann, Christian [VerfasserIn]   i
 Zeman, Florian [VerfasserIn]   i
 Weller, Michael [VerfasserIn]   i
 Proescholdt, Martin [VerfasserIn]   i
 Brawanski, Alexander [VerfasserIn]   i
 Pietsch, Thorsten [VerfasserIn]   i
 Wick, Wolfgang [VerfasserIn]   i
 Bogdahn, Ulrich [VerfasserIn]   i
 Hau, Peter [VerfasserIn]   i
Titel:Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas
Titelzusatz:a prospective single-arm monocentric phase-II study (RNOP-05)
Verf.angabe:Oliver Grauer, Christina Pascher, Christian Hartmann, Florian Zeman, Michael Weller, Martin Proescholdt, Alexander Brawanski, Thorsten Pietsch, Wolfgang Wick, Ulrich Bogdahn, Peter Hau
E-Jahr:2011
Jahr:4 March 2011
Umfang:9 S.
Fussnoten:Gesehen am 11.07.2022
Titel Quelle:Enthalten in: Journal of neuro-oncology
Ort Quelle:Dordrecht [u.a.] : Springer Science + Business Media B.V, 1983
Jahr Quelle:2011
Band/Heft Quelle:104(2011), 3, Seite 801-809
ISSN Quelle:1573-7373
Abstract:The objective of this prospective, monocentric phase-II pilot study was to evaluate toxicity and efficacy of neoadjuvant temozolomide (TMZ) and 13-cis retinoic acid (13-cRA) treatment in patients with newly diagnosed anaplastic gliomas after total or subtotal tumor resection. The primary endpoint of the study was median progression-free survival (PFS). Secondary endpoints were toxicity and PFS rates at 6, 12 and 24 months. Thirty-two adult patients were included in the study and treated with a median number of 10 TMZ and 13-cRA cycles (range 1-26). The majority of patients had favorable prognostic factors characterized by young age, complete resection, oligodendroglial histology, 1p/19q co-deletion, O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation and isocitrate dehydrogenase 1 (IDH1) mutation. Grade 3/4 myelotoxicity occurred in 5/32 patients, and about 90% of patients suffered from grade 2/3 adverse events attributable to 13-cRA. The median PFS was 37.8 months (95% CI 22.2-53.4). The 6-, 12- and 24-month PFS rates were 84.4, 75 and 42.4%. The extent of tumor resection was the only prognostic factor associated with better PFS. TMZ and 13-cRA treatment did not improve PFS when retrospectively compared to the TMZ-treated group within the randomized NOA-04 phase-III trial. In conclusion, 13-cRA addition to TMZ in a neoadjuvant setting showed acceptable toxicity, but did not yield an advantage in PFS in patients with newly diagnosed anaplastic gliomas after total or subtotal tumor resection.
DOI:doi:10.1007/s11060-011-0548-y
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1007/s11060-011-0548-y
 Volltext: https://link.springer.com/article/10.1007/s11060-011-0548-y
 DOI: https://doi.org/10.1007/s11060-011-0548-y
Datenträger:Online-Ressource
Sprache:eng
Bibliogr. Hinweis:Errata: Grauer, Oliver Martin, 1969 - : Erratum to
Sach-SW:13-cis retinoic acid
 1p/19q co-deletion
 Anaplastic glioma
 IDH1
 MGMT
 Temozolomide
K10plus-PPN:1809699614
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68939972   QR-Code
zum Seitenanfang